[go: up one dir, main page]

SG11201911864PA - Using nucleosome interacting protein domains to enhance targeted genome modification - Google Patents

Using nucleosome interacting protein domains to enhance targeted genome modification

Info

Publication number
SG11201911864PA
SG11201911864PA SG11201911864PA SG11201911864PA SG11201911864PA SG 11201911864P A SG11201911864P A SG 11201911864PA SG 11201911864P A SG11201911864P A SG 11201911864PA SG 11201911864P A SG11201911864P A SG 11201911864PA SG 11201911864P A SG11201911864P A SG 11201911864PA
Authority
SG
Singapore
Prior art keywords
interacting protein
protein domains
genome modification
targeted genome
enhance targeted
Prior art date
Application number
SG11201911864PA
Inventor
Fuqiang Chen
Xiao Ding
Yongmei Feng
Gregory D Davis
Original Assignee
Sigma Aldrich Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Aldrich Co Llc filed Critical Sigma Aldrich Co Llc
Publication of SG11201911864PA publication Critical patent/SG11201911864PA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102Mutagenizing nucleic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90Stable introduction of foreign DNA into chromosome
    • C12N15/902Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/80Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/80Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C07K2319/81Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/20Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/22Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/80Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11201911864PA 2017-07-11 2018-07-10 Using nucleosome interacting protein domains to enhance targeted genome modification SG11201911864PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762531222P 2017-07-11 2017-07-11
PCT/US2018/041454 WO2019014230A1 (en) 2017-07-11 2018-07-10 Using nucleosome interacting protein domains to enhance targeted genome modification

Publications (1)

Publication Number Publication Date
SG11201911864PA true SG11201911864PA (en) 2020-01-30

Family

ID=62916578

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201911864PA SG11201911864PA (en) 2017-07-11 2018-07-10 Using nucleosome interacting protein domains to enhance targeted genome modification

Country Status (17)

Country Link
US (3) US10604752B2 (en)
EP (2) EP3428274B1 (en)
JP (3) JP6994560B2 (en)
KR (3) KR102655021B1 (en)
CN (1) CN111183226A (en)
AU (3) AU2018299995B2 (en)
CA (1) CA3066790C (en)
DK (2) DK3428274T3 (en)
ES (2) ES2997490T3 (en)
FI (1) FI3988656T3 (en)
GB (3) GB2567917B (en)
IL (2) IL309801B2 (en)
LT (2) LT3988656T (en)
PL (2) PL3988656T3 (en)
PT (2) PT3988656T (en)
SG (1) SG11201911864PA (en)
WO (1) WO2019014230A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3204496A1 (en) 2014-10-10 2017-08-16 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
US20190127713A1 (en) 2016-04-13 2019-05-02 Duke University Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use
CN111183226A (en) 2017-07-11 2020-05-19 西格马-奥尔德里奇有限责任公司 Use of nucleosome interacting protein domains to enhance targeted genomic modifications
US11866726B2 (en) 2017-07-14 2024-01-09 Editas Medicine, Inc. Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
EP3740580A4 (en) 2018-01-19 2021-10-20 Duke University GENOMIC ENGINEERING WITH CRISPR-CAS SYSTEMS IN EUKARYOTES
KR102465067B1 (en) * 2018-02-15 2022-11-10 시그마-알드리치 컴퍼니., 엘엘씨 Engineered CAS9 System for Eukaryotic Genome Modification
SG11202009783WA (en) 2018-04-19 2020-11-27 Univ California Compositions and methods for gene editing
WO2020036653A2 (en) * 2018-04-25 2020-02-20 The Regents Of The University Of California Improved method for homology directed repair in cells
CN112424349A (en) 2018-06-04 2021-02-26 哥本哈根大学 Mutated Cpf1 endonucleases
WO2020006423A1 (en) 2018-06-29 2020-01-02 Editas Medicine, Inc. Synthetic guide molecules, compositions and methods relating thereto
WO2020187272A1 (en) * 2019-03-19 2020-09-24 上海邦耀生物科技有限公司 Fusion protein for gene therapy and application thereof
CN111718420B (en) * 2019-03-19 2021-09-14 华东师范大学 Fusion protein for gene therapy and application thereof
CN111718418B (en) * 2019-03-19 2021-08-27 华东师范大学 Fusion protein for enhancing gene editing and application thereof
SG11202111982UA (en) * 2019-05-13 2021-11-29 Emd Millipore Corp Synthetic self-replicating rna vectors encoding crispr proteins and uses thereof
EP4028514A1 (en) * 2019-09-09 2022-07-20 Beam Therapeutics Inc. Novel crispr enzymes, methods, systems and uses thereof
WO2021226555A2 (en) * 2020-05-08 2021-11-11 Duke University Chromatin remodelers to enhance targeted gene activation
WO2021224506A1 (en) * 2020-05-08 2021-11-11 Universitat Pompeu Fabra Crispr-cas homology directed repair enhancer
JP7769691B2 (en) * 2020-09-21 2025-11-13 コリア ユニバーシティ リサーチ アンド ビジネス ファウンデーション New and improved base editing or editing fusion proteins and uses thereof
KR102679001B1 (en) * 2020-09-21 2024-06-28 고려대학교 산학협력단 Compositions and methods for use of engineered base editing fusion protein
EP4230738A4 (en) * 2020-09-24 2024-11-20 Korea University Research and Business Foundation GENE EDITING COMPOSITION BASED ON PRIMARY EDITING WITH IMPROVED EDITING EFFICIENCY AND ITS USE
CN116745418A (en) * 2020-11-06 2023-09-12 成对植物服务股份有限公司 Compositions and methods for RNA-encoded DNA replacement of alleles
CN114507689B (en) * 2022-01-27 2024-01-16 山东大学 Method for improving eukaryotic gene editing efficiency and application thereof
CN115716880A (en) * 2022-12-07 2023-02-28 云舟生物科技(广州)股份有限公司 Nuclear localization fluorescent protein and application thereof
CN115948465B (en) * 2022-12-16 2025-09-19 中国农业科学院北京畜牧兽医研究所 Pig HAT1 gene modification system and application

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1456374A4 (en) 2001-11-26 2005-08-17 Advanced Cell Tech Inc METHODS FOR THE PRODUCTION AND USE OF REPROGRAMME HUMAN SOMATIC CELL CORES AND AUTOLOGOUS AND ISOGENIC HUMAN STEM CELLS
AU2004232928A1 (en) 2003-04-22 2004-11-04 Ibc Pharmaceuticals Polyvalent protein complex
US20130274129A1 (en) * 2012-04-04 2013-10-17 Geneart Ag Tal-effector assembly platform, customized services, kits and assays
KR102530118B1 (en) * 2012-07-25 2023-05-08 더 브로드 인스티튜트, 인코퍼레이티드 Inducible dna binding proteins and genome perturbation tools and applications thereof
CN108715602A (en) 2012-12-06 2018-10-30 西格马-奥尔德里奇有限责任公司 Genomic modification based on CRISPR and regulation and control
US20140273230A1 (en) * 2013-03-15 2014-09-18 Sigma-Aldrich Co., Llc Crispr-based genome modification and regulation
EP3744842A1 (en) * 2013-03-15 2020-12-02 The General Hospital Corporation Using truncated guide rnas (tru-grnas) to increase specificity for rna-guided genome editing
WO2015048577A2 (en) * 2013-09-27 2015-04-02 Editas Medicine, Inc. Crispr-related methods and compositions
WO2016036754A1 (en) * 2014-09-02 2016-03-10 The Regents Of The University Of California Methods and compositions for rna-directed target dna modification
WO2016049251A1 (en) * 2014-09-24 2016-03-31 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling mutations in leukocytes
EP3204496A1 (en) 2014-10-10 2017-08-16 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
US10190106B2 (en) 2014-12-22 2019-01-29 Univesity Of Massachusetts Cas9-DNA targeting unit chimeras
US20170369855A1 (en) 2014-12-24 2017-12-28 Dana-Farber Cancer Institute, Inc. Systems and methods for genome modification and regulation
EP3929286A1 (en) 2015-06-17 2021-12-29 Poseida Therapeutics, Inc. Compositions and methods for directing proteins to specific loci in the genome
US20160376610A1 (en) 2015-06-24 2016-12-29 Sigma-Aldrich Co. Llc Cell cycle dependent genome regulation and modification
US11339408B2 (en) 2015-08-20 2022-05-24 Applied Stemcell, Inc. Nuclease with enhanced efficiency of genome editing
US9926546B2 (en) 2015-08-28 2018-03-27 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
CN111183226A (en) 2017-07-11 2020-05-19 西格马-奥尔德里奇有限责任公司 Use of nucleosome interacting protein domains to enhance targeted genomic modifications

Also Published As

Publication number Publication date
IL309801B1 (en) 2024-08-01
GB2567917B (en) 2021-05-12
JP6994560B2 (en) 2022-02-21
AU2021245148A1 (en) 2021-11-04
JP7469285B2 (en) 2024-04-16
JP2022046532A (en) 2022-03-23
DK3428274T3 (en) 2021-11-15
EP3988656B9 (en) 2024-11-27
JP2024096783A (en) 2024-07-17
AU2021245148B2 (en) 2024-01-04
IL271197B2 (en) 2024-06-01
GB2598847A (en) 2022-03-16
DK3988656T3 (en) 2024-11-11
PL3988656T3 (en) 2024-12-16
CA3066790C (en) 2023-07-18
JP2020530287A (en) 2020-10-22
ES2997490T3 (en) 2025-02-17
EP3428274B1 (en) 2021-10-13
US10604752B2 (en) 2020-03-31
KR20230053732A (en) 2023-04-21
IL271197B1 (en) 2024-02-01
EP3988656A1 (en) 2022-04-27
US20210024916A1 (en) 2021-01-28
PT3428274T (en) 2021-11-05
GB202103935D0 (en) 2021-05-05
IL309801A (en) 2024-02-01
GB2593814B (en) 2022-01-05
BR112019028261A2 (en) 2020-07-14
CN111183226A (en) 2020-05-19
WO2019014230A1 (en) 2019-01-17
AU2018299995A1 (en) 2020-01-02
EP3988656B1 (en) 2024-09-18
PT3988656T (en) 2024-11-07
LT3988656T (en) 2024-11-11
IL309801B2 (en) 2024-12-01
GB201811358D0 (en) 2018-08-29
AU2018299995B2 (en) 2021-10-28
US12065642B2 (en) 2024-08-20
FI3988656T3 (en) 2024-10-29
KR20200021529A (en) 2020-02-28
CA3066790A1 (en) 2019-01-17
GB2567917A (en) 2019-05-01
US20200208135A1 (en) 2020-07-02
AU2022200851A1 (en) 2022-03-03
LT3428274T (en) 2021-11-25
AU2022200851B2 (en) 2023-12-14
ES2901629T3 (en) 2022-03-23
GB2593814A (en) 2021-10-06
KR102523217B1 (en) 2023-04-20
KR20240046316A (en) 2024-04-08
EP3428274A1 (en) 2019-01-16
GB202114520D0 (en) 2021-11-24
US12221606B2 (en) 2025-02-11
KR102655021B1 (en) 2024-04-04
IL271197A (en) 2020-01-30
GB2598847B (en) 2022-06-01
PL3428274T3 (en) 2022-01-03
US20190017042A1 (en) 2019-01-17

Similar Documents

Publication Publication Date Title
IL271197A (en) Using nucleosome interacting protein domains to enhance targeted genome modification
IL295358A (en) Using programmable dna binding proteins to enhance targeted genome modification
IL268894A (en) Therapeutic rna
IL272514A (en) Preparations and methods for genome modification
IL290733A (en) Conjugates of quaternized tubulysin compounds
SG11201707663SA (en) Lyophilization of rna
ZA201805634B (en) Conjugate of therapeutic enzymes
ZA201703163B (en) Rna guided eradication of human jc virus and other polyomaviruses
MA43570A (en) GENE THERAPY TO TREAT FAMILY HYPERCHOLESTEROLEMIA
EP3876936A4 (en) PITUITARY TUMORS REDUCTION METHODS
GB201711481D0 (en) Protein purification
EP3261631C0 (en) INHIBITION OF OLIG2 ACTIVITY
EP3076985C0 (en) COMPOSITION CONTAINING CLPB PROTEIN OVEREXPRESSING PROBIOTICS FOR THE TREATMENT OF OBESITY
LT3368044T (en) TREATMENT OF LIVER STEATOSIS RELATED TO OLIGO-OVULATION
EP3595688A4 (en) GENE THERAPY TO TREAT FAMILY HYPERCHOLESTERINEMIA
EP3302557A4 (en) IMPROVING THE THERAPEUTIC ACTIVITY OF AN IMMUNE CONTROL POINT INHIBITOR
GB201622116D0 (en) Treatment of liver disease
GB201704922D0 (en) Methods of protein stapling
EP3302067A4 (en) Use of proteins to control molluscs
GB201521547D0 (en) New therapeutic uses of enzyme inhibitors